Stroke AcuteStrokeAlarmEFFNCT06315192
Stroke Alarm Efficacy Trial
A study testing Stroke Alarm in people with Stroke Acute and Atrial Fibrillation, run by Region Skane at 10 sites in Sweden.
Trial summary
The aim of this study is to test the efficacy of the CE-marked wearable system Stroke Alarm to identify the onset of a stroke with unilateral arm motor deficit within 3 hours of onset. This is a multicenter, prospective observational single-arm trial with a registry-based propensity matched control population. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Stroke Acute, Atrial Fibrillation, TIA
- What is being tested?
- Stroke Alarm
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 500 participants
- Where
- 10 sitesSweden
- Study dates
- 5 Sep 2024to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 50 years or older
- Modified Rankin scale of 0-2.
- Diagnosed with either:
- Recent* transient ischemic attack (TIA, G45.9), AND:
- ABCD2 score of ≥6, OR:
- Atrial fibrillation OR:
Show all 18Show fewer
- Large artery atherosclerosis**.
- Recent* acute ischemic stroke (I63), AND:
- Atrial fibrillation, OR:
- Large artery atherosclerosis**. C. Atrial fibrillation/flutter (I48), AND
- None, or reduced dose of, oral anticoagulation medication***, AND
- CHA2DS2-VASC score ≥4.
- Recent* intracerebral hemorrhage (I61.9), AND:
- Atrial fibrillation.
- The patient has received the required information about the study and agrees in writing to participate.
- Smartphone user since at least 1 year.
- Within the last 2 weeks **Atherosclerosis in carotid, vertebral aortic arch or major intracerebral arteries according to CTA or ultrasound.
- Including all oral anticoagulation medication such as Warfarin and NOACs. Patients with reduced dose of a NOAC can be included, regardless if this is within the approved label, or if reduced dose is chosen off-label for other reasons. Treatment with antiplatelet medication is permissible.
Who cannot join
- Previous inclusion in this study.
- Arm motor deficit from any previous medical condition.
- Unable to give informed consent to participate in the study.
- Does not master any of the languages available within the Stroke Alarm smartphone app in speech and writing.
- Does not have access to a Stroke Alarm compatible smartphone.
- Deemed unable to handle the Stroke Alarm smartphone app, or participate in planned follow-up within the framework of the study due to other diseases or circumstances.
- Does not want to participate.
Trial locations and contacts
10 sites in 1 country. Contact the study team or a site near you to ask about taking part.
10 sites in 1 country
Sweden10 sites, 10 recruiting
- Recruiting
Sahlgrenska University Hospital
Gothenburg
Mikael Jerndal, MD, PhD, mikael.jerndal@vgregion.se
- Recruiting
Hässleholms sjukhus
Hässleholm, 28138
Magnus Esbjörnsson, MD, +46451298753, magnus.esbjornsson@med.lu.se
Magnus Esbjörnsson, MD
- Recruiting
Helsingborg lasarett
Helsingborg
Maria Macek, MD, 046 46171000, Maria.Macek@skane.se
- Recruiting
Karolinska University Hospital Huddinge
Huddinge, 14186
Michael Mazya, MD, PhD, +46709720277, michael.mazya@regionstockholm.se
Michael Mazya, MD, PhD
- Recruiting
Linköping university hospital
Linköping
Avan Sabir Rashid, MD, PhD, Avan.Sabir.Rashid@regionostergotland.se
- Recruiting
Skane University hospital
Lund, 22185
Irina Dragancea, MD, PhD, +46 46 171437 ext. +46-46173082, irina.dragancea@skane.se
Johan Wasselius, MD PhD, +46 46173082, johan.wasselius@gmail.com
- Recruiting
Skåne University Hospital Malmö
Malmö, 20502
Teresa Ullberg, MD, PhD, +46727434402, teresa.ullberg@med.lu.se
- Recruiting
Karolinska Sjukhuset
Stockholm
Michael Mazya, MD, PhD, +46 0851770000, michael.mazya@regionstockholm.se
- Recruiting
Södersjukhuset
Stockholm
Mihaela Romanitan, MD, PhD, mihaela.romanitan@regionstockholm.se
- Recruiting
Uppsala University hospital
Uppsala
Karl Sjölin, karl.sjolin@akademiska.se
About this study
The aim of this study is to test the efficacy of the CE-marked wearable system Stroke Alarm to identify the onset of a stroke with unilateral arm motor deficit within 3 hours of onset.
This is a multicenter, prospective observational single-arm trial with a registry-based propensity matched control population.
Read more
A total of 500 patients will be included in the trial. An interim analysis will determine if the stroke onset frequency is sufficient to determine the main outcome. Should the number of stroke events differ from what is expected at interim analysis, study enrollment will continue to increase cohort size.
Patients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study.
Patients with elevated stroke risk according assessed by presence of specific criteria associated with elevated risk caused by:
- recent TIA with an ABCD2 score of ≥6, large artery atherosclerosis or atrial fibrillation, OR
- recent ischemic stroke with large artery atherosclerosis or atrial fibrillation, without persisting arm motor deficit, OR
- atrial fibrillation with an CHA2DS2-Vasc score ≥ 4 without adequate anticoagulation OR
- recent hemorrhagic stroke with atrial fibrillation, without persisting arm motor deficit The combined efficacy goal is at least 60% sensitivity for Stroke Alarm b of stroke with unilateral arm motor deficit within 3 hours of onset (with a 95% confidence interval above 30%) and a specificity of at least 80% using a clinical stroke diagnosis as gold standard.
A control population matched for calendar year, age (± 5 years), sex, healthcare region, baseline stroke severity according to the National Institutes of Health Stroke Scale (NIHSS, ± 5 points), unilateral arm motor deficit (NIHSS item 5a/5b 1-4), presence of neglect/inattention (NIHSS item 11 1-2), atrial fibrillation, cohabitation status and pre-stroke functional level twill be identified in the Swedish national stroke registry, Riksstroke, and used for comparison.
Read the detailed description
Objectives and hypotheses of the clinical investigation The aim of this study is to test the ability and efficacy of the CE-marked wearable system Stroke Alarm to detect a stroke onset early.
The hypothesis is that the Stroke Alarm is able to indicate at least 60% of stroke cases with unilateral arm motor deficit within 3 hours of onset with a specificity of at least 80%.
Design of the clinical investigation This is a prospective single arm observational trial with a propensity-matched registry-derived control group.
All patients with a diagnosis of stroke (ischemic stroke or intracerebral hemorrhage) without arm motor deficits, TIA or atrial fibrillation at the participating hospitals that fulfill all inclusion critera and no exclusion criteria is asked for participation in the trial.
The patient is after the setup wearing the device continuously for three months.
An administrative follow-up is performed at 90-120 days following inclusion, the EPR is reviewed for any hospital admissions for stroke during the study period.
No standard care comparator will be used in this study, mainly because of lack of similar systems to compare with and blinding issues.
Simultaneous inclusion in other studies that require bracelets are not permitted, but inclusion in other clinical treatment trials, such as for drugs och medical devices that does not require bracelets, are acceptable.
Study population All patients (age ≥ 50 years) with a recent diagnosis of stroke (ischemic stroke or intracerebral hemorrhage) without arm motor deficits or TIA at the participating hospitals are candidates for participation in the trial. Patients have to be at increased risk for stroke, defined by ABCD2 score of ≥6 (TIA), presence of large artery atherosclerosis or atrial fibrillation (TIA and/or ischemic stroke), or atrial fibrillation (intracerebral hemorrhage). Patients with atrial fibrillation without adequate anticoagulation and a CHA2DS2-VAsc score ≥ 4 can be included at any time point.
Enrollment Patients with a diagnosis of stroke (ischemic stroke or intracerebral hemorrhage) without arm motor deficits, TIA or atrial fibrillation that fullfill all inclusion and have no exclusion criteria are included after signing the informed consent form at inclusion visit after oral and written information within the hospital or at an out-patient facility (described in Informed consent process, section 16).
Included subjects are added to the identification log stored in the Investigators Site File (ISF) that is located in locked research offices at the participating hospitals. The Identification log is under no circumstances shared or moved from the ISF that is located at participating hospital.
The patients are instructed to use the device continuously for three months. When setting-up the app on their smartphones they will be required to add at least one alarm recipient, but adding more alarm recipients is encouraged. The recipients are independent of study design and can be family members, friends or neighbors, as preferred by the subjects.
Device startup The study nurses manage the inclusion procedure that are recorded in the EPR and the administrative system according to the local regulations of the including center.
The wearable stroke indication system is given to the patient when accepting inclusion in the trial. The system will include a user manual with step-by-step instructions that are used during the activation of the investigational device, Stroke Alarm. The Study nurse may also assist in activation, including adding alarm recipients which is exactly the same as expected during clinical routine use.
The product is designed for continuous use for up to 6 months in a home environment and can also be used in a hospital environment. The devices will not be re-used for another subject and collected by the manufacturer at the end of the study.
The device is not MR-compatible. The included patient is the user of the device. Each participant will receive one unit of Stroke Alarm, consisting of a pair of sensor bracelets and one IFU. The smartphone app is downloaded from Apple's AppStore (iOS) or via Google Play (Android). Other operative systems can't be used.
The device is intended to be used continuously during the entire study period of 90 days. During the study the user is instructed to use the device according to the IFU. The user is instructed to use the device in his/her regular activities in the home environment continuously during the entire study period.
For the device to be fully functional, the user needs to activate and wear both sensor bracelets, install the Stroke Alarm app, complete the on-boarding and have at least one alarm recipient who has accepted the invitation to act as alarm recipient. Also, for the device to be fully functional, the user needs to be within Bluetooth connection from his/her smartphone, the smartphone needs to be active and have wifi- or 3G/4G/5G internet access.
At startup, the user invites Alarm recipients, who will be alerted via SMS messages in case the device indicates stroke by identifying arm motor deficiency that may be consistent with stroke and the initial indication is not abolished by the user. Any number of Alarm recipients can be chosen, typically they may be relatives, neighbors and friends. An Alarm recipient is not registered to the system unless he/she accepts his/her role as an Alarm recipient for the user. At least one confirmed Alarm recipient is necessary for the system to be operational. Alarm recipients can be added or removed during the study period. The choice of, and role for the Alarm recipients is identical in the study as in regular use. That means that the user will select Alarm recipients based on his/her own preferences and they are supposed to react to any alarms from the device as they would to the device in regular use. An Alarm recipient is not a study subject, and no informed consent is obtained. The identity of the Alarm recipients is not collected in the study.
During setup are the user testing the stroke test (Appendix A) that consists of 8 questions/tasks designed to mimic the items tested by the NIHSS and the different types of sound and/or vibration alarms (described bellow) for better understanding of the differences between them.
Similar to regular use of the device, the study subjects may contact the manufacturer's support-service for questions and support related to the device.
Alarm description A false indication is an indication made by the algorithm from imbalance of arm activity in the absence of a stroke. It can occur during everyday activity dominated by one arm. It will lead to a false alarm if it is not abolished by user tests.
Dedicated arm motion (Escalation step 1, Figure 2) is a specified gesture (draw a ball in the air) that is used to identify erroneous indications.
In-app test (Escalation step 2, Figure 2) is the test included in the Stroke Alarm smartphone app intended to abolish erroneous indications that are not eliminated by a dedicated arm motion (Escalation step 1).
A false alarm is a SMS alarm sent to the Alarm recipients based on an initial false indication made by the algorithm in the absence of a stroke with unilateral arm motor defecit.
SMS messages to the Alarm recipients generated by technical problems that affect the function of the device (for example loss of internet-connection or loss of Bluetooth-connection) is not considered false alarms.
If the user suffers a stroke and is not able to alert himself/herself and an arm paresis associated with the stroke is detected by the device, this will first generate a true indication manifested as vibration in the bracelet of the affected arm. If the user does not abolish this indication by a dedication arm movement, it will trigger a local alarm in the smartphone within 30 seconds. If the user does not open the smartphone app and complete the in-app stroke test within 10 minutes a SMS alarm is sent to all Alarm recipients. Alarm recipients are then expected to promptly act to ensure that the user is either confirmed to be well or is taken care of by healthcare, similar as if the user had called for help by any other means.
If the user suffers a stroke with unilateral arm weakness, and is unable to alert himself/herself and no arm paresis is detected by the device (false negative) the device has not contributed to patient care and stroke diagnosis, similar to if the device not was present. In this case the workflow is the same as without the device; which means that the patient will need to alert healthcare himself/herself, of by help of others who may be present at onset or who may discover the patient at a later timepoint.
The device does not contact health care services. This contact must be initiated by the user or by Alarm recipients alerted by the device or other means.
- Conditions
- Stroke Acute, Atrial Fibrillation, TIA
- Being tested
- Stroke Alarm
- Keywords
- Stroke, wearable, indication, sensor
- Medical subject headings
- Stroke, Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Stroke AlarmDevice
Patients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study.
| Study group | Role | What they receive |
|---|---|---|
| Stroke Alarm use | Experimental | The patients are provided with Stroke Alarm and instructed to use it in accordance with the IFU for a 3 months period. Receives: Device: Stroke Alarm |
What is being measured
The primary outcome is the main question the study is designed to answer.
Alarm from device within 3 hours of onset of stroke with unilateral arm motor deficit.
The alarm is recorded systematically from the device backend. The ground truth is gathered based on the medical records for stroke events during the study period.
Measured: From enrollment to the end of treatment at 3 months
Secondary outcomes (6)
Time from onset of stroke with unilateral arm motor deficit until alarm by device.
- Time from onset of stroke with unilateral arm motor deficit until arrival to first hospital.
Measured: From enrollment to the end of treatment at 3 months
Time from onset of stroke with unilateral arm motor deficit until arrival to first hospital.
The alarm is recorded systematically from the device backend. The ground truth is gathered based on the medical records for stroke events during the study period.
Measured: From enrollment to the end of treatment at 3 months.
Number of alarms indicated by the device within 3 hours of onset, in patients with a subsequent clinical diagnosis of stroke.
The alarm is recorded systematically from the device backend. The ground truth is gathered based on the medical records for stroke events during the study period.
Measured: From enrollment to the end of treatment at 3 months.
Number of alarms indicated by the device within 3 hours of onset, in patients with a subsequent clinical diagnosis of a stroke mimic.
The alarm is recorded systematically from the device backend. The ground truth is gathered based on the medical records for stroke events during the study period.
Measured: From enrollment to the end of treatment at 3 months.
Number of IVT and/or EVT treatments.
Number of IVT and/or EVT treatments during the study period.
Measured: From enrollment to the end of treatment at 3 months
Number of complications/adverse events generated by the device.
Any complications/adverse events generated by the device during the study period.
Measured: From enrollment to the end of treatment at 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Mar 2024
- Study start5 Sep 2024
- Primary completion31 Oct 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Stroke AcuteStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This is a multicenter, prospective observational single-arm trial with a registry-based propensity matched control population.
- Masking
- None (open label)
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Region Skane
- Sponsor type
- University, hospital or other
- Collaborators
- Karolinska University Hospital, Stockholm South General Hospital, Sahlgrenska University Hospital, Skane University Hospital, Hässleholm Hospital, Uppsala University Hospital, Helsingborgs Hospital, University Hospital, Linkoeping
- Responsible party
- Sponsor
- Investigators
- Ulrika Anderson, Ms., Study director, Lund University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06315192
- Sponsor's protocol ID
- CIV-22-10-041006
- Acronym
- StrokeAlarmEFF
- Status last verified
- Mar 2026
- First submitted
- 11 Mar 2024
- Last updated
- 30 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 30 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Stroke Alarm Efficacy Trial
- ClinicalTrials.gov ID
- NCT06315192
- Acronym / sponsor ID
- StrokeAlarmEFF / CIV-22-10-041006
- Conditions
- Stroke Acute, Atrial Fibrillation, TIA
- Keywords
- Stroke, wearable, indication, sensor
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Region SkaneUniversity, hospital or other
- Collaborators
- Karolinska University Hospital, Stockholm South General Hospital, Sahlgrenska University Hospital, Skane University Hospital, Hässleholm Hospital, Uppsala University Hospital, Helsingborgs Hospital, University Hospital, Linkoeping
- Study start
- 5 Sep 2024 (actual)
- Primary completion
- 31 Oct 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 18 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to test the efficacy of the CE-marked wearable system Stroke Alarm to identify the onset of a stroke with unilateral arm motor deficit within 3 hours of onset.
This is a multicenter, prospective observational single-arm trial with a registry-based propensity matched control population.
A total of 500 patients will be included in the trial. An interim analysis will determine if the stroke onset frequency is sufficient to determine the main outcome. Should the number of stroke events differ from what is expected at interim analysis, study enrollment will continue to increase cohort size.
Patients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study.
Patients with elevated stroke risk according assessed by presence of specific criteria associated with elevated risk caused by:
- recent TIA with an ABCD2 score of ≥6, large artery atherosclerosis or atrial fibrillation, OR
- recent ischemic stroke with large artery atherosclerosis or atrial fibrillation, without persisting arm motor deficit, OR
- atrial fibrillation with an CHA2DS2-Vasc score ≥ 4 without adequate anticoagulation OR
- recent hemorrhagic stroke with atrial fibrillation, without persisting arm motor deficit The combined efficacy goal is at least 60% sensitivity for Stroke Alarm b of stroke with unilateral arm motor deficit within 3 hours of onset (with a 95% confidence interval above 30%) and a specificity of at least 80% using a clinical stroke diagnosis as gold standard.
A control population matched for calendar year, age (± 5 years), sex, healthcare region, baseline stroke severity according to the National Institutes of Health Stroke Scale (NIHSS, ± 5 points), unilateral arm motor deficit (NIHSS item 5a/5b 1-4), presence of neglect/inattention (NIHSS item 11 1-2), atrial fibrillation, cohabitation status and pre-stroke functional level twill be identified in the Swedish national stroke registry, Riksstroke, and used for comparison.
Detailed description
Objectives and hypotheses of the clinical investigation The aim of this study is to test the ability and efficacy of the CE-marked wearable system Stroke Alarm to detect a stroke onset early.
The hypothesis is that the Stroke Alarm is able to indicate at least 60% of stroke cases with unilateral arm motor deficit within 3 hours of onset with a specificity of at least 80%.
Design of the clinical investigation This is a prospective single arm observational trial with a propensity-matched registry-derived control group.
All patients with a diagnosis of stroke (ischemic stroke or intracerebral hemorrhage) without arm motor deficits, TIA or atrial fibrillation at the participating hospitals that fulfill all inclusion critera and no exclusion criteria is asked for participation in the trial.
The patient is after the setup wearing the device continuously for three months.
An administrative follow-up is performed at 90-120 days following inclusion, the EPR is reviewed for any hospital admissions for stroke during the study period.
No standard care comparator will be used in this study, mainly because of lack of similar systems to compare with and blinding issues.
Simultaneous inclusion in other studies that require bracelets are not permitted, but inclusion in other clinical treatment trials, such as for drugs och medical devices that does not require bracelets, are acceptable.
Study population All patients (age ≥ 50 years) with a recent diagnosis of stroke (ischemic stroke or intracerebral hemorrhage) without arm motor deficits or TIA at the participating hospitals are candidates for participation in the trial. Patients have to be at increased risk for stroke, defined by ABCD2 score of ≥6 (TIA), presence of large artery atherosclerosis or atrial fibrillation (TIA and/or ischemic stroke), or atrial fibrillation (intracerebral hemorrhage). Patients with atrial fibrillation without adequate anticoagulation and a CHA2DS2-VAsc score ≥ 4 can be included at any time point.
Enrollment Patients with a diagnosis of stroke (ischemic stroke or intracerebral hemorrhage) without arm motor deficits, TIA or atrial fibrillation that fullfill all inclusion and have no exclusion criteria are included after signing the informed consent form at inclusion visit after oral and written information within the hospital or at an out-patient facility (described in Informed consent process, section 16).
Included subjects are added to the identification log stored in the Investigators Site File (ISF) that is located in locked research offices at the participating hospitals. The Identification log is under no circumstances shared or moved from the ISF that is located at participating hospital.
The patients are instructed to use the device continuously for three months. When setting-up the app on their smartphones they will be required to add at least one alarm recipient, but adding more alarm recipients is encouraged. The recipients are independent of study design and can be family members, friends or neighbors, as preferred by the subjects.
Device startup The study nurses manage the inclusion procedure that are recorded in the EPR and the administrative system according to the local regulations of the including center.
The wearable stroke indication system is given to the patient when accepting inclusion in the trial. The system will include a user manual with step-by-step instructions that are used during the activation of the investigational device, Stroke Alarm. The Study nurse may also assist in activation, including adding alarm recipients which is exactly the same as expected during clinical routine use.
The product is designed for continuous use for up to 6 months in a home environment and can also be used in a hospital environment. The devices will not be re-used for another subject and collected by the manufacturer at the end of the study.
The device is not MR-compatible. The included patient is the user of the device. Each participant will receive one unit of Stroke Alarm, consisting of a pair of sensor bracelets and one IFU. The smartphone app is downloaded from Apple's AppStore (iOS) or via Google Play (Android). Other operative systems can't be used.
The device is intended to be used continuously during the entire study period of 90 days. During the study the user is instructed to use the device according to the IFU. The user is instructed to use the device in his/her regular activities in the home environment continuously during the entire study period.
For the device to be fully functional, the user needs to activate and wear both sensor bracelets, install the Stroke Alarm app, complete the on-boarding and have at least one alarm recipient who has accepted the invitation to act as alarm recipient. Also, for the device to be fully functional, the user needs to be within Bluetooth connection from his/her smartphone, the smartphone needs to be active and have wifi- or 3G/4G/5G internet access.
At startup, the user invites Alarm recipients, who will be alerted via SMS messages in case the device indicates stroke by identifying arm motor deficiency that may be consistent with stroke and the initial indication is not abolished by the user. Any number of Alarm recipients can be chosen, typically they may be relatives, neighbors and friends. An Alarm recipient is not registered to the system unless he/she accepts his/her role as an Alarm recipient for the user. At least one confirmed Alarm recipient is necessary for the system to be operational. Alarm recipients can be added or removed during the study period. The choice of, and role for the Alarm recipients is identical in the study as in regular use. That means that the user will select Alarm recipients based on his/her own preferences and they are supposed to react to any alarms from the device as they would to the device in regular use. An Alarm recipient is not a study subject, and no informed consent is obtained. The identity of the Alarm recipients is not collected in the study.
During setup are the user testing the stroke test (Appendix A) that consists of 8 questions/tasks designed to mimic the items tested by the NIHSS and the different types of sound and/or vibration alarms (described bellow) for better understanding of the differences between them.
Similar to regular use of the device, the study subjects may contact the manufacturer's support-service for questions and support related to the device.
Alarm description A false indication is an indication made by the algorithm from imbalance of arm activity in the absence of a stroke. It can occur during everyday activity dominated by one arm. It will lead to a false alarm if it is not abolished by user tests.
Dedicated arm motion (Escalation step 1, Figure 2) is a specified gesture (draw a ball in the air) that is used to identify erroneous indications.
In-app test (Escalation step 2, Figure 2) is the test included in the Stroke Alarm smartphone app intended to abolish erroneous indications that are not eliminated by a dedicated arm motion (Escalation step 1).
A false alarm is a SMS alarm sent to the Alarm recipients based on an initial false indication made by the algorithm in the absence of a stroke with unilateral arm motor defecit.
SMS messages to the Alarm recipients generated by technical problems that affect the function of the device (for example loss of internet-connection or loss of Bluetooth-connection) is not considered false alarms.
If the user suffers a stroke and is not able to alert himself/herself and an arm paresis associated with the stroke is detected by the device, this will first generate a true indication manifested as vibration in the bracelet of the affected arm. If the user does not abolish this indication by a dedication arm movement, it will trigger a local alarm in the smartphone within 30 seconds. If the user does not open the smartphone app and complete the in-app stroke test within 10 minutes a SMS alarm is sent to all Alarm recipients. Alarm recipients are then expected to promptly act to ensure that the user is either confirmed to be well or is taken care of by healthcare, similar as if the user had called for help by any other means.
If the user suffers a stroke with unilateral arm weakness, and is unable to alert himself/herself and no arm paresis is detected by the device (false negative) the device has not contributed to patient care and stroke diagnosis, similar to if the device not was present. In this case the workflow is the same as without the device; which means that the patient will need to alert healthcare himself/herself, of by help of others who may be present at onset or who may discover the patient at a later timepoint.
The device does not contact health care services. This contact must be initiated by the user or by Alarm recipients alerted by the device or other means.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This is a multicenter, prospective observational single-arm trial with a registry-based propensity matched control population.
| Arm | Type | Receives |
|---|---|---|
| Stroke Alarm use | Experimental | Device: Stroke AlarmThe patients are provided with Stroke Alarm and instructed to use it in accordance with the IFU for a 3 months period. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (18 listed)
- Age 50 years or older
- Modified Rankin scale of 0-2.
- Diagnosed with either:
- The patient has received the required information about the study and agrees in writing to participate.
- Smartphone user since at least 1 year.
Key exclusion criteria (7 listed)
- Previous inclusion in this study.
- Arm motor deficit from any previous medical condition.
- Unable to give informed consent to participate in the study.
- Does not master any of the languages available within the Stroke Alarm smartphone app in speech and writing.
- Does not have access to a Stroke Alarm compatible smartphone.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Stroke AlarmPatients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study. | Device | Stroke Alarm use |
Primary outcome
Alarm from device within 3 hours of onset of stroke with unilateral arm motor deficit.
Time frame: From enrollment to the end of treatment at 3 months
The alarm is recorded systematically from the device backend. The ground truth is gathered based on the medical records for stroke events during the study period.
6 secondary outcomes
Time from onset of stroke with unilateral arm motor deficit until alarm by device.
Time frame: From enrollment to the end of treatment at 3 months
Time from onset of stroke with unilateral arm motor deficit until arrival to first hospital.
Time frame: From enrollment to the end of treatment at 3 months.
Number of alarms indicated by the device within 3 hours of onset, in patients with a subsequent clinical diagnosis of stroke.
Time frame: From enrollment to the end of treatment at 3 months.
Number of alarms indicated by the device within 3 hours of onset, in patients with a subsequent clinical diagnosis of a stroke mimic.
Time frame: From enrollment to the end of treatment at 3 months.
Number of IVT and/or EVT treatments.
Time frame: From enrollment to the end of treatment at 3 months
Number of complications/adverse events generated by the device.
Time frame: From enrollment to the end of treatment at 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jun 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Stroke Acute
Not yet recruitingPhase 3
Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence
Acute Ischemic Stroke
Recruiting
Rapid Local Ischemic Postconditioning on Stroke After Thrombectomy
Acute Ischemic Stroke
Recruiting
Safety and Feasibility of NRICM301 Added to Usual Care for Adults With Acute Ischemic Stroke
Acute Ischemic Stroke
Not yet recruitingObservational study
Tenecteplase in Acute Ischemic Stroke Under Different Transfer Models
Acute Ischemic Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ulrika Anderson, Ms. study director
Lund University
10 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Stroke Alarm in people with Stroke Acute and Atrial Fibrillation, run by Region Skane at 10 sites in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Magnus Esbjörnsson, MD (800-555-5555 ext. 46-451-298753, magnus.esbjornsson@skane.se), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Alarm from device within 3 hours of onset of stroke with unilateral arm motor deficit. (time frame: From enrollment to the end of treatment at 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jun 2026.